These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 33990175)

  • 1. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study.
    Jeong SJ; Lee SE; Shin DH; Park IB; Lee HS; Kim KA
    BMC Nephrol; 2021 May; 22(1):177. PubMed ID: 33990175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria.
    Nakhleh A; Abdul-Ghani M; Gazit S; Gross A; Livnat I; Greenbloom M; Yarden A; Khazim K; Shehadeh N; Melzer Cohen C
    Diabetes Obes Metab; 2024 Aug; 26(8):3058-3067. PubMed ID: 38680053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.
    Tanaka A; Shimabukuro M; Okada Y; Sugimoto K; Kurozumi A; Torimoto K; Hirai H; Node K;
    Cardiovasc Diabetol; 2020 Jun; 19(1):85. PubMed ID: 32534578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barriers to early diagnosis of chronic kidney disease and use of sodium-glucose cotransporter-2 inhibitors for renal protection: A comprehensive review and call to action.
    Czupryniak L; Mosenzon O; Rychlík I; Clodi M; Ebrahimi F; Janez A; Kempler P; Małecki M; Moshkovich E; Prázný M; Sourij H; Tankova T; Timar B
    Diabetes Obes Metab; 2024 Oct; 26(10):4165-4177. PubMed ID: 39140231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal Protection and Safety of Sodium-glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.
    Zhou T; Yao K; Xie Y; Lin Y; Wang J; Chen X
    Curr Pharm Des; 2023; 29(21):1659-1670. PubMed ID: 37537933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes.
    Edmonston D; Lydon E; Mulder H; Chiswell K; Lampron Z; Marsolo K; Goss A; Ayoub I; Shah RC; Chang AR; Ford DE; Jones WS; Fonesca V; Machineni S; Fort D; Butler J; Hunt KJ; Pitlosh M; Rao A; Ahmad FS; Gordon HS; Hung AM; Hwang W; Bosworth HB; Pagidipati NJ
    JAMA Netw Open; 2024 Jun; 7(6):e2418808. PubMed ID: 38922613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry.
    Pierce JB; Vaduganathan M; Fonarow GC; Ikeaba U; Chiswell K; Butler J; DeVore AD; Heidenreich PA; Huang JC; Kittleson MM; Joynt Maddox KE; Linganathan KK; McDermott JJ; Owens AT; Peterson PN; Solomon SD; Vardeny O; Yancy CW; Greene SJ
    JAMA Cardiol; 2023 Jul; 8(7):652-661. PubMed ID: 37212192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early reduction in albuminuria is associated with a steeper 'dip' in initial estimated glomerular filtration rate but favourable long-term kidney outcomes in people with diabetes receiving sodium-glucose cotransporter-2 inhibitors.
    Kao YW; Yen KC; Chen SW; Chao TF; Chan YH
    Diabetes Obes Metab; 2024 Sep; 26(9):3868-3879. PubMed ID: 38951860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan.
    Tangri N; Rastogi A; Nekeman-Nan C; Hong LS; Ozaki A; Franzén S; Sofue T
    Adv Ther; 2024 Mar; 41(3):1151-1167. PubMed ID: 38240949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early biomarkers of diabetic kidney disease. A focus on albuminuria and a new combination of antidiabetic agents.
    Carretero Gómez J; Ena J; Seguí Ripoll JM; Carrasco-Sanchez FJ; Gómez Huelgas R; Mateos Polo L; Varela Aguilar JM; Suárez Tembra JM; Arévalo-Lorido JC;
    Int J Clin Pract; 2020 Oct; 74(10):e13586. PubMed ID: 32533906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
    Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
    Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease.
    Yen FS; Hwu CM; Liu JS; Wu YL; Chong K; Hsu CC
    Ann Intern Med; 2024 Jun; 177(6):693-700. PubMed ID: 38684099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the use of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and chronic kidney disease in tertiary care: a SwissDiab Study.
    Hösli PS; Renström F; Laimer M; Cavelti-Weder C; Gastaldi G; Lehmann R; Brändle M
    BMJ Open Diabetes Res Care; 2024 Jun; 12(3):. PubMed ID: 38901857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
    Cahn A; Melzer-Cohen C; Pollack R; Chodick G; Shalev V
    Diabetes Obes Metab; 2019 Feb; 21(2):340-348. PubMed ID: 30207040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes.
    Miyoshi H; Kameda H; Yamashita K; Nakamura A; Kurihara Y
    J Diabetes Investig; 2019 Nov; 10(6):1510-1517. PubMed ID: 31026373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DAPA-CKD: Significant Victory for CKD with or without Diabetes.
    Patel AB; Mistry K; Verma A
    Trends Endocrinol Metab; 2021 Jun; 32(6):335-337. PubMed ID: 33676827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis.
    Ma C; Li X; Li W; Li Y; Shui F; Zhu P
    Int Urol Nephrol; 2023 Dec; 55(12):3167-3174. PubMed ID: 37046125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
    Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M
    Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.